Why the study?
Does catheter ablation improve long-term morbidity and stroke risk in patients with asymptomatic atrial fibrillation?
Does catheter ablation improve long-term morbidity and stroke risk in patients with asymptomatic atrial fibrillation?
While AF ablation is currently indicated for symptom reduction, future prospective studies are needed to determine if it improves long-term morbidity and stroke risk, which could expand its use to asymptomatic patients.
Supports symptom-based AF ablation indications; leaves open stroke/morbidity benefits in asymptomatic patients, requiring prospective trials.
Ablation therapy for atrial fibrillation (AF) has been shown to be more efficient than medical treatment alone. Long-term success of AF ablation is still around 50% after one ablation and higher after two, with a substantial amount of asymptomatic recurrences in formerly symptomatic patients. Given the lack of evidence for superiority of rhythm control over rate control in terms of stroke reduction and mortality, AF ablation remains a treatment for symptom reduction only, although ablation has never been a part of these studies. There is early evidence that ablation could decrease the long-term risk of stroke; however, prospective studies are needed to assess whether this is the case and how patients with a successful ablation can be identified. If AF ablation can be shown to improve long-term morbidity, it could also become a reasonable treatment for patients with asymptomatic AF.
No takes yet. Share an insight, caveat, or question.
Kochhäuser et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: